<DOC>
	<DOCNO>NCT00296946</DOCNO>
	<brief_summary>A phase II double blind clinical trial investigate effect ipratropium spray versus placebo spray patient Parkinson 's disease .</brief_summary>
	<brief_title>Ipratropium Spray Drooling Saliva Parkinson 's Disease</brief_title>
	<detailed_description>Background : Excessive drooling saliva ( sialorrhoea ) common complication Parkinson ’ disease ( PD ) . Unfortunately current medication , rely anticholinergic property , often induce systemic side effect , confusion , hallucination urinary retention . Aim : We therefore hypothesise local application anticholinergic aerosol spray mouth would reduce sialorrhea PD without induce systemic side-effects . Method : A double blind , randomise , placebo-controlled cross-over trial muscarinic antagonist , ipratropium bromide patient bothersome drool idiopathic Parkinson ’ disease . All patient recruit Movement Disorders Clinic , Toronto Western Hospital inform consent obtain . Patients randomise receive ipratropium bromide , 1- 2 metered dos ( spray ) active drug ( 21 g per meter dose ) match placebo , maximum 4 time per day , double-blind , cross-over design use randomisation table . Total treatment length two week limb study 1-2 week wash period . The primary outcome measure objective measure saliva production . Dental roll insert mouth 5 min patient instruct swallow sit upright . The weight dental roll insertion calculate measure saliva production . The secondary outcome measure subjective measure saliva patient caregiver record level saliva production day 2 week treatment use validated subjective rating scale ass drool severity frequency . In addition , parkinsonism rat use UPDRS part I – IV adverse event record . The score measure saliva production follow ipratropium bromide placebo treatment compare use appropriate pair t-tests . Results scale assess subjective measure saliva production UPDRS rating compare via paired non-parametric Wilcoxon match pairs test . 20 patient recruit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Male female patient idiopathic PD currently experience bothersome drooling ( United Parkinson ’ Disease Rating Scale ( UPDRS ) item 6 , rating 2 high ) eligible study . Patients must stable medication regimen precede onemonth runin period . In addition , patient caregiver must able complete daily record card , patient must able tolerate oral dental roll 5minute period saliva measurement . Patients take acetylcholinesterase inhibitor , cholinergic agent , anticholinergic agent , history glaucoma , clinically significant urinary outflow obstruction urinary retention , active psychosis hallucination , allergy peanut soybean .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>Sialorrhoea</keyword>
</DOC>